Exact Mass: 266.16303419999997

Exact Mass Matches: 266.16303419999997

Found 84 metabolites which its exact mass value is equals to given mass value 266.16303419999997, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

TRIBUTYL PHOSPHATE

Phosphoric acid tri-N-butyl ester

C12H27O4P (266.1646872)

D020011 - Protective Agents > D011837 - Radiation-Protective Agents

Practolol

N-[4-[(2S)-2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide

C14H22N2O3 (266.16303419999997)

Practolol is only found in individuals that have used or taken this drug. It is a beta-adrenergic antagonist that has been used in the emergency treatment of cardiac arrhythmias. [PubChem]Like other beta-adrenergic antagonists, practolol competes with adrenergic neurotransmitters such as catecholamines for binding at sympathetic receptor sites. Like propranolol and timolol, practolol binds at beta(1)-adrenergic receptors in the heart and vascular smooth muscle, inhibiting the effects of the catecholamines epinephrine and norepinephrine and decreasing heart rate, cardiac output, and systolic and diastolic blood pressure. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Same as: D05587 Practolol is a potent and selective β1-adrenergic receptor antagonist. Practolol can be used for the research of cardiac arrhythmias[1][2][3].

atenolol

(±)-2-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide

C14H22N2O3 (266.16303419999997)

C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents CONFIDENCE standard compound; INTERNAL_ID 4076 CONFIDENCE Reference Standard (Level 1) CONFIDENCE standard compound; INTERNAL_ID 1106 Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris[1][2].

Atenolol

(±)-2-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide

C14H22N2O3 (266.16303419999997)

Atenolol is a so-called beta1-selective (or cardioselective) drug. That means that it exerts greater blocking activity on myocardial beta1-receptors than on beta2 ones in the lung. The beta2 receptors are responsible to keep the bronchial system open. If these receptors are blocked, bronchospasm with serious lack of oxygen in the body can result. However, due to its cardioselective properties, the risk of bronchospastic reactions if using atenolol is reduced compared to nonselective drugs as propranolol. Nonetheless, this reaction may also be encountered with atenolol, particularly with high doses. Extreme caution should be exerted if atenolol is given to asthma patients, who are particularly at risk; the dose should be as low as possible. If an asthma attack occurs, the inhalation of a beta2-mimetic antiasthmatic, such as hexoprenalin or salbutamol, will usually suppress the symptoms.; Atenolol (trade name Tenormin) can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, and treatment of myocardial infarction after the acute event. Patients with compensated congestive heart failure may be treated with atenolol as a co medication (usually together with an ACE inhibitor, a diuretic and a digitalis-glycoside, if indicated). In patients with congestive heart failure, it reduces the need for and the consumption of oxygen of the heart muscle. It is very important to start with low doses, as atenolol reduces also the muscular power of the heart, which is an undesired effect in congestive heart failure. [HMDB] Atenolol is a so-called beta1-selective (or cardioselective) drug. That means that it exerts greater blocking activity on myocardial beta1-receptors than on beta2 ones in the lung. The beta2 receptors are responsible to keep the bronchial system open. If these receptors are blocked, bronchospasm with serious lack of oxygen in the body can result. However, due to its cardioselective properties, the risk of bronchospastic reactions if using atenolol is reduced compared to nonselective drugs as propranolol. Nonetheless, this reaction may also be encountered with atenolol, particularly with high doses. Extreme caution should be exerted if atenolol is given to asthma patients, who are particularly at risk; the dose should be as low as possible. If an asthma attack occurs, the inhalation of a beta2-mimetic antiasthmatic, such as hexoprenalin or salbutamol, will usually suppress the symptoms. Atenolol (trade name Tenormin) can be used to treat cardiovascular diseases such as hypertension, coronary heart disease, arrhythmias, and treatment of myocardial infarction after the acute event. Patients with compensated congestive heart failure may be treated with atenolol as a co medication (usually together with an ACE inhibitor, a diuretic and a digitalis-glycoside, if indicated). In patients with congestive heart failure, it reduces the need for and the consumption of oxygen of the heart muscle. It is very important to start with low doses, as atenolol reduces also the muscular power of the heart, which is an undesired effect in congestive heart failure. C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris[1][2].

(3xi,6E)-1,7-Diphenyl-6-hepten-3-ol

trans－1,7－Diphenyl－5-hydroxy-1－hepten

C19H22O (266.1670562)

(3xi,6E)-1,7-Diphenyl-6-hepten-3-ol is found in beverages. (3xi,6E)-1,7-Diphenyl-6-hepten-3-ol is a constituent of seeds of Curcuma xanthorrhiza (Java turmeric)

Bucolome

5-butyl-3-cyclohexyl-6-hydroxy-2,3,4,5-tetrahydropyrimidine-2,4-dione

C14H22N2O3 (266.16303419999997)

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic

CC(=O)Nccccccn1C=CC(=O)C(O)=C1C

N-[6-(3-Hydroxy-2-methyl-4-oxo-1,4-dihydropyridin-1-yl)hexyl]ethanimidate

C14H22N2O3 (266.16303419999997)

Dilatan

Biopharma brand OF trimetazidine dihydrochloride

C14H22N2O3 (266.16303419999997)

COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents C - Cardiovascular system > C01 - Cardiac therapy Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Potassium myristate

Potassium tetradecanoic acid

C14H27KO2 (266.1648022)

It is used as a food additive .

atenolol

(±)-2-[4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide

C14H22N2O3 (266.16303419999997)

C - Cardiovascular system > C07 - Beta blocking agents > C07A - Beta blocking agents > C07AB - Beta blocking agents, selective C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents CONFIDENCE standard compound; EAWAG_UCHEM_ID 169 Atenolol ((RS)-Atenolol) is a cardioselective β1-adrenergic receptor blocker, with a Ki of 697 nM at β1-adrenoceptor in guine pig left ventricle membrane. Atenolol can be used for the research of hypertension and angina pectoris[1][2].

3-Hydroxy-4-(3-methyl-2-butenyl)bibenzyl

C19H22O (266.1670562)

Lauryl sulfate

C12H26O4S (266.1551716)

D013501 - Surface-Active Agents Annotation level-3 CONFIDENCE standard compound; INTERNAL_ID 2407 CONFIDENCE standard compound; INTERNAL_ID 4066 CONFIDENCE standard compound; INTERNAL_ID 8761

TRIISOBUTYL PHOSPHATE

tris(2-methylpropyl) phosphate

C12H27O4P (266.1646872)

CONFIDENCE standard compound; INTERNAL_ID 2468 CONFIDENCE standard compound; INTERNAL_ID 8808 CONFIDENCE standard compound; INTERNAL_ID 8248 CONFIDENCE standard compound; INTERNAL_ID 4188

TENTATIVELY IDENTIFIED SPECTRUM ONLY!!!!!!!!!; Extracted (without noise removal) from ZWI_N: mz265_15_rt18_47_HCD60_C12-AS; CONFIDENCE Tentative identification: best match only (Level 3)

Tri-N-butyl phosphate

C12H27O4P (266.1646872)

MS2 deconvoluted using MS2Dec from all ion fragmentation data, MetaboLights identifier MTBLS1040; STCOOQWBFONSKY-UHFFFAOYSA-N_STSL_0219_Tri-N-butyl phosphate_0002fmol_190326_S2_LC02MS02_076; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I. MS2 deconvoluted using CorrDec from all ion fragmentation data, MetaboLights identifier MTBLS1040; Spectrum acquired as described in Naz et al 2017 PMID 28641411. Preparation and submission to MassBank of North America by Chaleckis R. and Tada I.